Avicenna.AI

Based in France, Avicenna. ai SAS develops innovative artificial intelligence solutions for emergency radiology, focusing on the rapid detection of critical conditions in CT scans. Avicenna. ai SAS, founded in 2018 in La Ciotat, France, specializes in AI-driven diagnostic tools for emergency radiology.

The company has secured a total of EUR 3. 04 mn in funding, with its most recent Series A round on March 9, 2023, co-led by Cemag Invest and Innovacom. The company has completed three deals to date and is privately held. Avicenna.

AI specializes in delivering advanced artificial intelligence (AI) solutions designed specifically for emergency radiology and the detection of incidental findings in CT scans. The company's primary product offerings include CINA-ICH, which identifies suspected intracranial hemorrhages, CINA-LVO for detecting large vessel occlusions in ischemic strokes, and CINA-ASPECTS, an AI-based quantification tool that assesses acute ischemic strokes using the Alberta Stroke Program Early CT Score. Additional solutions encompass CINA-PE for pulmonary embolism detection, CINA-AD for aortic dissection identification, and CINA-iPE, which detects lung blood clots in patients undergoing imaging for other conditions. These tools significantly enhance the speed and accuracy of diagnoses, thereby allowing medical professionals to focus on urgent cases.

Avicenna. AI's client base includes hospitals and healthcare facilities primarily located in Europe, North America, and select markets in Asia, catering to radiologists and healthcare providers who require timely and efficient diagnostics. Avicenna. AI operates on a subscription-based revenue model, where healthcare institutions and radiology departments pay for access to its suite of AI tools.

In the most recent year, 2022, the company reported a revenue of EUR 238,126. 90 with an EBITDA of EUR -442,198. 10. Transactions typically involve annual or multi-year agreements that allow users to integrate these advanced tools into their existing workflows, ensuring seamless access to features such as automated detection alerts and prioritization of critical cases.

Key products, such as CINA-ICH and CINA-PE, form the core of the company's offerings, driving revenue through partnerships with healthcare systems that seek to enhance their diagnostic capabilities. In March 2023, Avicenna. AI raised EUR 3. 04 million in Series A funding to broaden its product offerings into new medical fields and increase the adoption of its solutions across the globe.

The company aims to introduce additional AI products and target expansion into new geographic regions, although specific markets and timelines have not been detailed at this time. The recent funding will support these initiatives, enhancing Avicenna. AI's capabilities in medical diagnostics.